Medical Oncology

Myelodysplastic Syndromes

Questions discussed in this category

When do you utilize lenalidomide in patients with MDS without del(5q)?

Are there particular mutations (eg SF3B1) or syndromes (eg MDS/MPN overlaps such as MDS/MPN-RS-T) where you are more apt to using lenalidomide?

1 Answer available

Is there currently a role for adding venetoclax to a hypomethylating agent (HMA) after failure of single-agent HMA therapy in MDS?

Can results from emerging AML data be extrapolated to high risk MDS populations? Is there data to guide the choice of continuing the HMA in combinati...

1 Answer available

Does isolated del(5q) have the same prognostic implications for post-PV secondary myelofibrosis as it does in MDS?

Given the rarity of this in MF, is it still predictive of response to lenalidomide therapy?

1 Answer available

What is your preferred first line treatment for patients with high risk MDS who are not candidates for transplant?

1 Answer available

What is the best strategy after initial treatment with hypomethylating agents for high grade myelodysplatic syndromes, mainly for responders who became transfusion independent?

Do we continue the hypomethylating agent indefinitely?

1 Answer available

How do you choose between azacitidine and decitabine when deciding to treat a patient with MDS with a hypomethylating agent?

1 Answer available

Papers discussed in this category

The Lancet. Oncology, 2009-03

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-05-15

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Cancer, 2011-06-15

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

American journal of hematology, 2009-09

A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.

Cancer, 2010-08-15

Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.

The New England journal of medicine, 2016-11-24

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

The Lancet. Haematology, 2018-01

Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.

Therapeutic advances in hematology, 2012-04

Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.

J Clin Oncol, 2021 Jan 13

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.

Medical Oncology

Myelodysplastic Syndromes

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology